TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Stock
Certificat
DE000CJ60FK4
| Market Closed - Börse Stuttgart 02:59:23 2024-06-07 EDT | ||
| 21.71 EUR | +0.14% |
|
| Current month | +6.95% | ||
| 1 month | +16.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 21.71 | +0.14% |
| 24-06-06 | 21.68 | +2.46% |
| 24-06-05 | 21.16 | +4.29% |
| 24-06-04 | 20.29 | -1.46% |
| 24-06-03 | 20.59 | +1.43% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 02:59 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | CJ60FK |
| ISIN | DE000CJ60FK4 |
| Date issued | 2019-01-03 |
| Strike | 165.3 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.71 € |
|---|---|
| Lowest since issue | 0.058 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- Certificat
